Hermetica Superfood Encyclopedia
The Short Answer
Chromium histidinate delivers trivalent chromium chelated to L-histidine, enhancing insulin signaling through GLUT translocation, AMPK activation, and modulation of IRS-1 and PPAR-gamma pathways to improve cellular glucose uptake. In rat models of high-fat-diet-induced insulin resistance, CrHis supplementation combined with biotin produced the most significant improvements in HOMA-IR, fasting glucose, insulin levels, and lipid profiles compared to chromium picolinate and control conditions.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordchromium histidinate benefits
Chromium Histidinate — botanical close-up
Health Benefits
**Insulin Sensitivity Improvement**
CrHis augments insulin receptor substrate-1 (IRS-1) signaling and reduces negative regulators of insulin pathways, leading to measurable reductions in HOMA-IR in animal models of metabolic dysfunction.
**Glucose Metabolism Support**
The compound promotes translocation of glucose transporter proteins (GLUTs) to cell membranes, increasing peripheral glucose uptake and lowering fasting blood glucose concentrations in both animal and limited human studies.
**AMPK Pathway Activation**
CrHis activates AMP-activated protein kinase (AMPK), a master metabolic regulator that drives cellular glucose uptake independently of insulin, offering a complementary mechanism for glycemic control.
**Lipid Profile Modulation**
Human supplementation studies have reported reductions in serum triglycerides and increases in HDL cholesterol, with animal data corroborating improvements in total cholesterol and LDL fractions under high-fat dietary conditions.
**Oxidative Stress Attenuation**
Supplementation with CrHis was associated with significantly lower levels of 8-OH-2dG (p=0.028), a marker of oxidative DNA damage, and a trend toward reduced 8-isoprostane levels (p=0.081), suggesting a protective effect against reactive oxygen species.
**Beta Cell Preservation**
In diabetic animal models, chromium histidinate supplementation was associated with partial recovery of pancreatic beta cell function and attenuation of macroangiopathy, suggesting potential protective roles in progressive metabolic disease.
**Anti-Inflammatory Signaling**
CrHis has been shown to modulate NF-κB protein activity in preclinical models, which may reduce pro-inflammatory cytokine signaling associated with insulin resistance and metabolic syndrome.
Origin & History
Natural habitat
Chromium histidinate (CrHis) is a synthetic chelated mineral compound in which trivalent chromium (Cr³⁺) is coordinately bound to the amino acid L-histidine. It is not derived from a botanical or geographic source but is manufactured through controlled chemical synthesis in pharmaceutical and nutraceutical settings. The chelation to histidine is designed to enhance gastrointestinal absorption, stability, and tissue bioavailability compared to inorganic chromium salts.
“Chromium histidinate is an entirely modern pharmaceutical innovation with no history of use in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbal practice. Interest in chromium as a nutritional element began in the 1950s when Schwarz and Mertz identified a 'glucose tolerance factor' (GTF) in brewer's yeast that contained chromium, prompting decades of research into chromium's role in carbohydrate metabolism. The chelation of chromium to histidine specifically emerged from later research efforts to improve upon the bioavailability limitations of inorganic chromium salts and to develop alternatives to chromium picolinate, which raised some safety concerns regarding oxidative DNA damage at high doses. There are no traditional preparations, folk remedies, or ethnobotanical records associated with CrHis, as its synthesis and characterization are products of late 20th and early 21st century nutritional biochemistry.”Traditional Medicine
Scientific Research
The evidence base for chromium histidinate specifically is limited, consisting primarily of animal studies in rats and cats, with only indirect support from broader human chromium supplementation trials. In a controlled feline study (n=16), CrHis supplementation at 800 µg/day for 56 days significantly elevated serum chromium levels (1.68 to 3.88 mg/L, p=0.027), with fructosamine trends suggesting improved glycemic control. Rat studies using high-fat diet models demonstrated that CrHis, particularly when combined with biotin, outperformed chromium picolinate in improving HOMA-IR, fasting insulin, glucose, leptin, and lipid parameters. Human clinical evidence is extrapolated from chromium supplementation trials broadly (e.g., Bahijiri 2000 reporting improved glucose control and HDL increase), but large, well-powered RCTs specific to the histidinate chelate form in human populations are absent, and existing human chromium trials have produced conflicting results across outcomes.
Preparation & Dosage
Traditional preparation
**Capsule/Tablet (Chelated Supplement)**
Standard human supplementation doses used in research have ranged from 200–1000 µg elemental chromium daily as CrHis; 200–400 µg/day is common in commercial products.
**Combined Formulations**
2–10 mg biotin), as preclinical data indicate synergistic improvements in insulin sensitivity and lipid metabolism when combined
CrHis is frequently co-formulated with biotin (e.g., .
**Animal/Veterinary Use**
Studied at 800 µg/day in cats and at varied ppb concentrations in cat chow; veterinary formulations differ from human-grade products.
**Timing**
Supplementation is typically taken with meals to coincide with postprandial insulin release and glucose flux, potentially maximizing GLUT translocation effects.
**Standardization**
Products should specify elemental chromium content as Cr³⁺; the histidinate chelate form should be confirmed, as bioavailability and safety profiles differ from chromium picolinate or chromium chloride.
**Upper Tolerable Intake**
The U.S. Institute of Medicine has not established a formal Tolerable Upper Intake Level (UL) for trivalent chromium; however, doses exceeding 1000 µg/day in clinical contexts have been associated with adverse events including hypoglycemia in insulin-dependent individuals.
Nutritional Profile
Chromium histidinate is not a whole food and thus has no meaningful macronutrient profile. Its primary nutritional significance lies in its delivery of elemental trivalent chromium (Cr³⁺), an essential trace mineral required in microgram quantities. The histidine component contributes an imidazole-containing amino acid that serves as the chelating ligand; at supplemental doses, the histidine content is nutritionally negligible relative to dietary intake. Chromium itself is present in trace amounts in foods such as brewer's yeast, broccoli, grape juice, and whole grains, typically at 1–13 µg per serving. The chelated form is designed to optimize bioavailability of Cr³⁺ by protecting it from alkaline hydrolysis in the gastrointestinal tract, though precise comparative absorption percentages for CrHis versus other forms have not been rigorously quantified in peer-reviewed human pharmacokinetic studies.
How It Works
Mechanism of Action
Chromium histidinate delivers Cr³⁺ into target tissues where it is proposed to interact with a low-molecular-weight chromium-binding protein (chromodulin/LMWCr), amplifying insulin receptor tyrosine kinase activity and downstream phosphorylation of IRS-1, thereby sensitizing cells to insulin. Concurrently, CrHis activates AMPK, an energy-sensing kinase that phosphorylates downstream substrates to stimulate GLUT4 translocation to the plasma membrane, increasing glucose influx independently of direct insulin receptor engagement. The compound also modulates PPAR-gamma transcriptional activity, influencing adipogenesis, lipid storage gene expression, and systemic insulin sensitivity, while suppressing NF-κB-mediated inflammatory gene transcription that otherwise impairs insulin signal transduction. The histidine ligand itself may contribute bioavailability advantages by protecting Cr³⁺ from hydrolysis and precipitation in the gastrointestinal tract, facilitating mucosal absorption via amino acid transport mechanisms.
Clinical Evidence
No large-scale randomized controlled trials have been conducted specifically on chromium histidinate in human subjects, representing a significant gap in the clinical evidence base. The most robust available data come from controlled animal experiments: HFD rat models show CrHis+biotin combinations yielding statistically significant improvements in insulin resistance indices and lipid markers, with apparent superiority over chromium picolinate. Cat studies (n=16) demonstrated significant serum chromium accumulation and trends toward improved glycemic markers, though sample sizes are insufficient to draw definitive conclusions. Human chromium supplementation data broadly suggest benefits for glucose control and lipid profiles in some populations, but evidence quality is inconsistent, and chromium histidinate-specific human RCT data are not currently available to confirm superiority over other chelated forms.
Safety & Interactions
At doses up to 1000 µg/day, chromium histidinate appears generally tolerated in short-term studies, but adverse events have been reported with chromium supplementation broadly, including acute generalized exanthematous pustulosis (characterized by erythematous pustular eruptions, fever, edema, leukocytosis, and eosinophilia), rhabdomyolysis (reported in a 24-year-old taking chromium picolinate alongside other supplements), and clinically significant hypoglycemia (documented in a 29-year-old diabetic patient using 1000 µg/day chromium with concurrent insulin therapy). The most critical drug interaction is with insulin and other glucose-lowering agents (sulfonylureas, GLP-1 agonists, SGLT-2 inhibitors), where additive hypoglycemic effects pose a meaningful clinical risk requiring dose monitoring and medical supervision. Safety data specific to chromium histidinate in pregnant or lactating women are absent; given the lack of established safety evidence, use in these populations should be avoided unless under direct medical supervision. Long-term safety data beyond 12 weeks are limited, and individuals with renal impairment should exercise caution given chromium's renal excretion pathway.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
CrHisChromium(III) histidinateTrivalent chromium histidinateChromium-histidine chelate
Frequently Asked Questions
What is chromium histidinate used for?
Chromium histidinate is primarily used as a dietary supplement to support glucose metabolism and insulin sensitivity. It delivers trivalent chromium chelated to the amino acid histidine, which activates insulin signaling pathways, promotes GLUT translocation, and activates AMPK to improve cellular glucose uptake, making it relevant for individuals with insulin resistance or metabolic syndrome.
Is chromium histidinate better than chromium picolinate?
Preclinical data from high-fat-diet rat models suggest CrHis may outperform chromium picolinate (CrPic) in improving HOMA-IR, fasting glucose, and lipid profiles, particularly when combined with biotin. However, no direct head-to-head human RCTs currently exist to confirm this superiority in clinical settings, so both forms remain used without definitive comparative human evidence.
What is the recommended dosage of chromium histidinate?
Human supplementation research has used doses up to 1000 µg/day of elemental chromium as CrHis, while commercial products commonly provide 200–400 µg/day. Animal studies used 800 µg/day in cats, and doses should be taken with meals to align with postprandial insulin and glucose dynamics; individuals on insulin or glucose-lowering medications should only use CrHis under medical supervision due to hypoglycemia risk.
Are there any side effects or safety concerns with chromium histidinate?
Chromium supplementation has been associated with adverse events including acute generalized exanthematous pustulosis (a skin reaction with fever and pustular eruptions), rhabdomyolysis at high doses alongside other supplements, and hypoglycemia when combined with insulin therapy. These events were primarily reported with chromium picolinate and high-dose chromium broadly; CrHis-specific adverse event data are limited, but the risks are considered class-level concerns applicable to all supplemental chromium forms.
Can chromium histidinate help with weight loss or body composition?
While chromium supplementation is sometimes marketed for weight loss or lean muscle support, the available clinical trial evidence does not reliably support these claims for any chromium chelate form, including CrHis. Animal studies show improvements in leptin and lipid parameters, and better glycemic control may indirectly support weight management, but human RCT evidence specifically demonstrating body composition benefits from CrHis is currently absent.
How does chromium histidinate improve insulin sensitivity compared to other chromium forms?
Chromium histidinate works by enhancing insulin receptor substrate-1 (IRS-1) signaling and suppressing negative regulators of insulin pathways, mechanisms that are more directly targeted than other chromium forms. This approach leads to measurable improvements in HOMA-IR scores, a key marker of insulin resistance, particularly in individuals with metabolic dysfunction. The histidinate chelation may improve bioavailability and cellular uptake compared to inorganic chromium sources, allowing for more efficient pathway modulation.
Does chromium histidinate interact with blood sugar medications like metformin or insulin?
Chromium histidinate enhances insulin sensitivity and glucose uptake, which means it may potentiate the effects of blood sugar-lowering medications, potentially increasing hypoglycemia risk. Individuals taking metformin, insulin, or other diabetes medications should consult their healthcare provider before supplementing with chromium histidinate to ensure proper dosing adjustments. Concurrent use may require more frequent blood glucose monitoring to maintain safe levels.
What does the research evidence show about chromium histidinate's effectiveness for metabolic health?
Current research demonstrates that chromium histidinate produces measurable reductions in insulin resistance markers (HOMA-IR) in animal models of metabolic dysfunction through its specific effects on GLUT translocation and insulin signaling pathways. While mechanistic studies show promise, most published evidence comes from preclinical and animal research; human clinical trials remain limited compared to other chromium forms. Further large-scale human studies are needed to establish optimal dosing and efficacy in diverse populations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w chromium-histidinate curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
